[go: up one dir, main page]

ZA969016B - Solubilisation methods. - Google Patents

Solubilisation methods.

Info

Publication number
ZA969016B
ZA969016B ZA9609016A ZA969016A ZA969016B ZA 969016 B ZA969016 B ZA 969016B ZA 9609016 A ZA9609016 A ZA 9609016A ZA 969016 A ZA969016 A ZA 969016A ZA 969016 B ZA969016 B ZA 969016B
Authority
ZA
South Africa
Prior art keywords
solubilisation
methods
solubilisation methods
Prior art date
Application number
ZA9609016A
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of ZA969016B publication Critical patent/ZA969016B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA9609016A 1995-10-25 1996-10-25 Solubilisation methods. ZA969016B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods

Publications (1)

Publication Number Publication Date
ZA969016B true ZA969016B (en) 1998-04-28

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609016A ZA969016B (en) 1995-10-25 1996-10-25 Solubilisation methods.

Country Status (12)

Country Link
EP (1) EP0857061A1 (en)
JP (1) JP2000502990A (en)
KR (1) KR19990067028A (en)
CN (1) CN1202818A (en)
AU (1) AU704292B2 (en)
BR (1) BR9611343A (en)
CA (1) CA2235487A1 (en)
GB (1) GB9521805D0 (en)
NO (1) NO981864L (en)
NZ (1) NZ320442A (en)
WO (1) WO1997015289A1 (en)
ZA (1) ZA969016B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602007009377D1 (en) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
DK2240155T3 (en) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Devices, formulations and methods for the delivery of several beneficial agents
LT2462246T (en) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc IMMEDIATE IMPLEMENTATION AND / OR TERMINATION OF IMMEDIATE STATIONARY SUPPLY
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (en) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmaceutical compositions for topical treatment of virus infections
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
WO1997015289A1 (en) 1997-05-01
AU704292B2 (en) 1999-04-15
GB9521805D0 (en) 1996-01-03
NO981864D0 (en) 1998-04-24
BR9611343A (en) 1999-12-28
KR19990067028A (en) 1999-08-16
CA2235487A1 (en) 1997-05-01
NO981864L (en) 1998-06-24
AU7317896A (en) 1997-05-15
NZ320442A (en) 1999-10-28
EP0857061A1 (en) 1998-08-12
JP2000502990A (en) 2000-03-14
CN1202818A (en) 1998-12-23

Similar Documents

Publication Publication Date Title
ZA967315B (en) Biphenylamides.
MX213417B (en) Phenylpyridazinones.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
ZA979199B (en) Aminothiophenecarboxamides.
ZA976168B (en) 3-Ureido-pyridofurans and -pyridothiophenes.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA977206B (en) Arylalkanoylpyridazines.
ZA961955B (en) Indazolecarboxamides.
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
MXPA99002581A (en) Dredging apparatus.
ZA969016B (en) Solubilisation methods.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA969625B (en) 25-Hydroxy-16-ene-26, 27-bishomo-cholecalciferols
ZA966603B (en) Therapeutic method.
ZA966399B (en) Endothelin-receptor-antagonists.
ZA97572B (en) 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA976022B (en) Cycloalkano-pyridines.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA966750B (en) Halogenobenzimidazoles.
ZA971466B (en) Endothelin-receptor-antagonists.
ZA967314B (en) Carbamoylcarboxamides.
ZA966699B (en) Substituted 2-phenylpyridines.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA971474B (en) Endothelin-receptor-antagonists.
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols